Research Paper Volume 12, Issue 10 pp 9825—9839
Association between metabolic syndrome and endometrial cancer risk: a systematic review and meta-analysis of observational studies
- 1 Department of Obstetrics and Gynecology, Shengjing Hospital of China Medical University, Shenyang, China
Received: January 29, 2020 Accepted: April 20, 2020 Published: May 22, 2020https://doi.org/10.18632/aging.103247
How to Cite
Copyright © 2020 Wang et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Existing evidence has revealed inconsistent results on the association between metabolic syndrome (MetS) and endometrial cancer (EC) risk. Herein, we aim to better understand this association. Systematic searches of PubMed, EMBASE, and Web of Science through 12 December 2019 were conducted. Observational studies that provided risk estimates of MetS and EC risk were eligible. The quality of the included studies was judged based on the Newcastle–Ottawa scale. Summary odds ratios (ORs) and 95% confidence intervals (CIs) were calculated using a random-effects model. Six studies, comprising 17,772 EC cases and 150,371 participants were included. MetS, diagnosed according to the criteria of the National Cholesterol Education Program—Third Adult Treatment Panel, was associated with an increased risk of EC (OR: 1.62; 95% CI = 1.26–2.07) with substantial heterogeneity (I2 = 78.3%). Furthermore, we found that women with MetS, diagnosed according to the criteria of the International Diabetes Federation, had a significantly higher risk of EC compared to healthy controls (OR: 1.45; 95% CI = 1.16–1.81; I2 = 64.6%). Our findings were generally consistent with the main results in the majority of prespecified subgroups, as well as in sensitivity analyses. In conclusion, MetS is associated with EC risk.
EC: endometrial cancer; MetS: metabolic syndrome; NCEP-ATP III: National Cholesterol Education Program—Third Adult Treatment Panel; IDF: International Diabetes Federation; OR: odds ratio; CI: confidence interval; LKB1–AMPK: liver kinase B1–AMP–activated protein kinase; BMI: body mass index; HDL-C: high-density lipoprotein-cholesterol.